[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 x o o (Check One): o o o For Period Ended: December 31, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[x o x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company ¨ x Documents Incorporated by Reference: None. 2 FORM 10-K ANNUAL REPORT FISCAL YEAR ENDED DECEMBER 31, 2015 TABLE OF CONTENTS PAGE] [EX-10.1 2 ex101.htm] [EX-10.2 3 ex102.htm] [EX-10.4 4 ex104.htm] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the "Company"), the principal and accumulated interest totaled USD1,354,567 and USD57,758 respectively as of December 31, 2015. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 30, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 8 ex321.htm]
[x o x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company ¨ x Documents Incorporated by Reference: None. 2 FORM 10-K ANNUAL REPORT FISCAL YEAR ENDED DECEMBER 31, 2015 TABLE OF CONTENTS PAGE] [EX-10.1 2 ex101.htm] [EX-10.2 3 ex102.htm] [EX-10.4 4 ex104.htm] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the "Company"), the principal and accumulated interest totaled USD1,354,567 and USD57,758 respectively as of December 31, 2015. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 30, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 8 ex321.htm]
[W ashington FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES SINOVAC BIOTECH LTD. Antigua, West Indies Not Applicable (State or other jurisdiction (I.R.S. Employer Identification of incorporation or organization) Number) No. 39 Shangdi Xi Road, Haidian District, Beijing 100085 People’s Republic of China Not Applicable (Zip Code) Title of each class to be so registered ___________________________________ Name of each]
[SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent Rights Agreement Dated as of March 28, 2016 RIGHTS AGREEMENT Agreement Company Rights Agent Rights Agreement, dated as of March 28, 2016 (this “ RECITALS Board Right Section 1.6 Record Date Sections 3.1 and 7.1 Series A Preferred Shares provided, however, Section 22 WHEREAS, the Board of Directors (the] [Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights The Rights Plan is designed to assure that all of the Company’s shareholders receive fair and equal treatment in the event of any proposed takeover of the Company and to guard against partial tender offers, open market accumulations and other abusive or coercive tactics to gain] []
[SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent Rights Agreement Dated as of March 28, 2016 RIGHTS AGREEMENT Agreement Company Rights Agent Rights Agreement, dated as of March 28, 2016 (this “ RECITALS Board Right Section 1.6 Record Date Sections 3.1 and 7.1 Series A Preferred Shares provided, however, Section 22 WHEREAS, the Board of Directors (the] [Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights The Rights Plan is designed to assure that all of the Company’s shareholders receive fair and equal treatment in the event of any proposed takeover of the Company and to guard against partial tender offers, open market accumulations and other abusive or coercive tactics to gain] []
[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
